Development of a Hepatic Liability Panel of Assays to Study Drug-Induced Liver Injury
Drug discovery currently represents a major innovation gap between the development of high-risk medicines and patient needs. Drug-induced liver injury (DILI) is a predominant reason for drug attritions, market withdrawals, and restricted use of drugs through black-box warnings. DILI is typically missed until late-stage discovery resulting in the costly termination of discovery programmes. Several publications have identified key molecular mechanisms that are said to contribute to DILI in man. A combined testing approach in models that assessed these individual markers for hepatotoxicity, would help improve the sensitivity and specificity of individual assays and help improve the overall predictability of DILI during early drug discovery thus reducing early compound attritions.